A-DIREKT is a vertically integrated biotechnology company that manages
the full production cycle in-house — from chemical synthesis and
plant-based extraction to GMP-compliant pharmaceutical manufacturing
and final quality control.
This structure allows us to maintain consistent quality standards,
reduce reliance on external contractors, and optimize production
timelines.
Eight facilities. Five countries. Nine disciplines. Zero outsourcing. From intercontinental grow operations for biomass to R&D and GMP production in the Czech Republic, a distribution center in France, and reach across Europe and the United States — every step of our value chain is owned and operated by A-DIREKT.
Custom synthesis from milligram to multi-kilogram scale. Jacketed reactors, Schlenk lines, low-temperature capability — all in-house. Because we also own the analytical step, every compound ships with HPLC purity data generated on our instruments.
GMP-qualified lines for granulation, tableting, encapsulation, and film coating. Vertical integration means a formulation moves from development through stability studies to commercial batch release without ever leaving our facility.
LC-MS/MS, GC-MS/MS, preparative LC, three HPLC systems, ICP for heavy metals, and a dedicated microbiology suite. Company-owned and operated — not outsourced to a third-party lab.
Capsules, tablets, sachets, and liquid formulations manufactured at scale. Full EU regulatory compliance including novel food dossiers. Our integrated supply chain takes a concept from prototype to shelf-ready product with no external dependencies.
Functional products formulated around specific bioavailability targets. With formulation, production, and testing all kept in-house, each batch undergoes full potency and dissolution verification before release.
Emulsion stability, preservative efficacy testing, regulatory documentation, and packaging — handled end-to-end. Vertical integration means the output is a finished product, not a handoff to another vendor.
Ethanol, supercritical CO₂, hydroethanolic — matched to the target compound. Extracts move directly into our analytical lab for profiling and into our production lines for formulation. No intermediaries.
When off-the-shelf hardware doesn't fit, we design and build it ourselves. Custom reactors, extraction systems, and processing skids — another layer of vertical integration that eliminates dependence on equipment suppliers.
Incoming material testing, in-process controls, batch release, ongoing stability — all performed by our own team on our own instruments. Full traceability from raw material intake to final product release.
This visualisation illustrates the binding interaction between a small-molecule ligand and a seven-transmembrane G-protein coupled receptor. The ligand enters through the extracellular vestibule and settles into the orthosteric binding pocket formed by transmembrane helices III, V, VI, and VII.
Understanding receptor-ligand dynamics at this level is central to our drug discovery pipeline — from designing new compounds to verifying binding affinity through in silico modelling and in vitro cell-based assays.
A-DIREKT was founded on a single principle: full ownership of the value chain. Early reliance on external partners for synthesis, analytics, and production introduced delays and limited oversight of quality. In response, the company systematically internalised each capability, expanding operations across eight facilities and five countries to achieve end-to-end control.
The result is an integrated workflow in which a synthesised compound proceeds directly to analytical characterisation within the same organisation. This is not merely operational efficiency — it is the defining structural advantage of vertical integration.
Every product — pharmaceutical, supplement, cosmetic — passes through our own analytical pipeline before release. No outsourced certificates, no third-party dependencies, no assumptions.
Tandem mass spectrometry. Sub-ppb quantitation for pharmacokinetics, impurity identification, and multi-residue screening.
Triple-quad volatiles. Residual solvents, pesticide residues, environmental contaminants — single-run detection and quantification.
Single-quad liquid chromatography–mass spectrometry for routine identification and quantitative screening.
Gas chromatography–mass spectrometry for volatile compound profiling, terpene analysis, and residual solvent identification.
Two systems running potency assays, impurity profiling, and dissolution testing in parallel.
ICP-grade elemental analysis. Pb, Cd, Hg, As to ICH Q3D and European Pharmacopoeia limits.
Cell-based assays for bioactivity, cytotoxicity, and pharmacological evaluation without animal models.
Dedicated clean room. Total aerobic count, yeast and mold, pathogen screening, endotoxin testing.
Blending, granulation, tableting, encapsulation, coating. All IQ/OQ/PQ qualified.
Fast identity confirmation, reaction monitoring, purity screening. The daily tools of synthesis QC.
Gotthardská 25/7
160 00 Praha 6-Bubeneč, Czech Republic
VAT ID: CZ25954946
ID: 25954946